• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Noel G. Boyle Discusses Benefits of Dabigatran Versus Warfarin for Treatment of Atrial Fibrillation


Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are at risk for stroke.

In addition, Dr. Boyle discusses the benefits of dabigatran (Brand name: Pradaxa) versus warfarin for the treatment of patients with atrial fibrillation. According to Dr. Boyle, advantages of dabigatran include no patient monitoring, fixed dosing, and less drug interactions. Disadvantages of dabigatran include twice daily dosing and no easy method for monitoring, according to Dr. Boyle.

Related Videos
Virginia Kaklamani, MD | image credit: uthscsa.edu
Ruben A. Mesa, MD, president and executive director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Landman family
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
Related Content
© 2023 MJH Life Sciences
All rights reserved.